Wenn Sie das Fenster schließen, wird Ihre Konfiguration nicht gespeichert, es sei denn, Sie haben Ihren Artikel in die Bestellung aufgenommen oder zu Ihren Favoriten hinzugefügt.
Klicken Sie auf OK, um das MILLIPLEX® MAP-Tool zu schließen oder auf Abbrechen, um zu Ihrer Auswahl zurückzukehren.
Wählen Sie konfigurierbare Panels & Premixed-Kits - ODER - Kits für die zelluläre Signaltransduktion & MAPmates™
Konfigurieren Sie Ihre MILLIPLEX® MAP-Kits und lassen sich den Preis anzeigen.
Konfigurierbare Panels & Premixed-Kits
Unser breites Angebot enthält Multiplex-Panels, für die Sie die Analyten auswählen können, die am besten für Ihre Anwendung geeignet sind. Unter einem separaten Register können Sie das Premixed-Cytokin-Format oder ein Singleplex-Kit wählen.
Kits für die zelluläre Signaltransduktion & MAPmates™
Wählen Sie gebrauchsfertige Kits zur Erforschung gesamter Signalwege oder Prozesse. Oder konfigurieren Sie Ihre eigenen Kits mit Singleplex MAPmates™.
Die folgenden MAPmates™ sollten nicht zusammen analysiert werden: -MAPmates™, die einen unterschiedlichen Assaypuffer erfordern. -Phosphospezifische und MAPmate™ Gesamtkombinationen wie Gesamt-GSK3β und Gesamt-GSK3β (Ser 9). -PanTyr und locusspezifische MAPmates™, z.B. Phospho-EGF-Rezeptor und Phospho-STAT1 (Tyr701). -Mehr als 1 Phospho-MAPmate™ für ein einziges Target (Akt, STAT3). -GAPDH und β-Tubulin können nicht mit Kits oder MAPmates™, die panTyr enthalten, analysiert werden.
.
Bestellnummer
Bestellinformationen
St./Pkg.
Liste
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Wählen Sie bitte Spezies, Panelart, Kit oder Probenart
Um Ihr MILLIPLEX® MAP-Kit zu konfigurieren, wählen Sie zunächst eine Spezies, eine Panelart und/oder ein Kit.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Spezies
Panelart
Gewähltes Kit
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
96-Well Plate
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
Weitere Reagenzien hinzufügen (MAPmates erfordern die Verwendung eines Puffer- und Detektionskits)
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Platzsparende Option Kunden, die mehrere Kits kaufen, können ihre Multiplex-Assaykomponenten in Kunststoffbeuteln anstelle von Packungen erhalten, um eine kompaktere Lagerung zu ermöglichen.
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Das Produkt wurde in Ihre Bestellung aufgenommen
Sie können nun ein weiteres Kit konfigurieren, ein Premixed-Kit wählen, zur Kasse gehen oder das Bestell-Tool schließen.
MAB1548
Sigma-AldrichAnti-Myosin Antibody, heavy chain β
Detect Myosin using this Anti-Myosin Antibody, heavy chain β validated for use in WB, IH.
More>>Detect Myosin using this Anti-Myosin Antibody, heavy chain β validated for use in WB, IH. Less<<
Anti-Myosin Antibody, heavy chain β: SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.
MYH7 encodes the cardiac muscle beta (or slow) isoform of myosin. Changes in the relative abundance of MYH7 and MYH6 (the alpha, or fast, isoform of cardiac myosin heavy chain) correlate with the contractile velocity of cardiac muscle. Mutations in MYH7 are associated with familial hypertrophic cardiomyopathy.
FUNCTION: SwissProt: P12883 # Muscle contraction. SIZE: 1935 amino acids; 223097 Da SUBUNIT: Muscle myosin is a hexameric protein that consists of 2 heavy chain subunits (MHC), 2 alkali light chain subunits (MLC) and 2 regulatory light chain subunits (MLC-2). SUBCELLULAR LOCATION: Cytoplasm, myofibril. Note=Thick filaments of the myofibrils. DOMAIN: SwissProt: P12883 The rodlike tail sequence is highly repetitive, showing cycles of a 28-residue repeat pattern composed of 4 heptapeptides, characteristic for alpha-helical coiled coils. DISEASE: SwissProt: P12883 # Defects in MYH7 are the cause of familial hypertrophic cardiomyopathy type 1 (CMH1) [MIM:192600]; also designated FHC or HCM. Hypertrophic cardiomyopathy is a heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The prevalence of the disease in the general population is 0.2%. FHC is clinically heterogeneous, with inter- and intrafamilial variations ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. & Defects in MYH7 are the cause of myosin storage myopathy [MIM:608358]. In this disorder, muscle biopsy shows type 1 fiber predominance and increased interstitial fat and connective tissue. Inclusion bodies consisting of the beta cardiac myosin heavy chain are present in the majority of type 1 fibers, but not in type 2 fibers. & Defects in MYH7 are a cause of dilated cardiomyopathy (CMD) [MIM:115200]. CMD is a disorder characterized by cardiac dilation and reduced systolic function. & Defects in MYH7 are the cause of Laing early-onset distal myopathy (MPD1) [MIM:160500]. MPD1 is an autosomal dominant disorder which differs from other distal myopathies in that onset is as early as 4 years of age. Selective weakness of the anterior tibial muscles is followed by weakness of the finger extensors and selected proximal muscle groups such as the hip abductors and rotators, the shoulder abductors and the sternocleidomastoids. SIMILARITY: Contains 1 IQ domain. & Contains 1 myosin head-like domain. MISCELLANEOUS: Each myosin heavy chain can be split into 1 light meromyosin (LMM) and 1 heavy meromyosin (HMM). It can later be split further into 2 globular subfragments (S1) and 1 rod-shaped subfragment (S2). & The cardiac alpha isoform is a 'fast' ATPase myosin, while the beta isoform is a 'slow' ATPase.
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage Conditions
Maintain at -20°C in undiluted aliquots for up to 12 months. Avoid repeated freeze/thaw cycles.
Many studies have compared the genetic and epigenetic profiles of human induced pluripotent stem cells (hiPSCs) to human embryonic stem cells (hESCs) and yet the picture remains unclear. To address this, we derived a population of neural precursor cells (NPCs) from the H1 (WA01) hESC line and generated isogenic iPSC lines by reprogramming. The gene expression and methylation profile of three lines were compared to the parental line and intermediate NPC population. We found no gene probe with expression that differed significantly between hESC and iPSC samples under undifferentiated or differentiated conditions. Analysis of the global methylation pattern also showed no significant difference between the two PSC populations. Both undifferentiated populations were distinctly different from the intermediate NPC population in both gene expression and methylation profiles. One point to note is that H1 is a male line and so extrapolation to female lines should be cautioned. However, these data confirm our previous findings that there are no significant differences between hESCs and hiPSCs at the gene expression or methylation level.
Hyperoxia-induced hypertrophy and ion channel remodeling in left ventricle. Panguluri, SK; Tur, J; Fukumoto, J; Deng, W; Sneed, KB; Kolliputi, N; Bennett, ES; Tipparaju, SM American journal of physiology. Heart and circulatory physiology
304
H1651-61
2013
Ventricular arrhythmias account for high mortality in cardiopulmonary patients in intensive care units. Cardiovascular alterations and molecular-level changes in response to the commonly used oxygen treatment remains unknown. In the present study we investigated cardiac hypertrophy and cardiac complications in mice subjected to hyperoxia. Results demonstrate that there is a significant increase in average heart weight to tibia length (22%) in mice subjected to hyperoxia treatment vs. normoxia. Functional assessment was performed in mice subjected to hyperoxic treatment, and results demonstrate impaired cardiac function with decreased cardiac output and heart rate. Staining of transverse cardiac sections clearly demonstrates an increase in the cross-sectional area from hyperoxic hearts compared with control hearts. Quantitative real-time RT-PCR and Western blot analysis indicated differential mRNA and protein expression levels between hyperoxia-treated and control left ventricles for ion channels including Kv4.2 (-2 ± 0.08), Kv2.1 (2.54 ± 0.48), and Scn5a (1.4 ± 0.07); chaperone KChIP2 (-1.7 ± 0.06); transcriptional factors such as GATA4 (-1.5 ± 0.05), Irx5 (5.6 ± 1.74), NFκB1 (4.17 ± 0.43); hypertrophy markers including MHC-6 (2.17 ± 0.36) and MHC-7 (4.62 ± 0.76); gap junction protein Gja1 (4.4 ± 0.8); and microRNA processing enzyme Drosha (4.6 ± 0.58). Taken together, the data presented here clearly indicate that hyperoxia induces left ventricular remodeling and hypertrophy and alters the expression of Kv4.2 and MHC6/7 in the heart.
Imaging of myocardial infarction in dogs and humans using monoclonal antibodies specific for human myosin heavy chains. Léger, Joc., et al. J. Am. Coll. Cardiol., 18:473-484 (1991)
1991
Histochemistry of ventricular heavy-chain myosins in cardiomyopathic Syrian hamsters treated with D-600. Jasmin, G, et al. Proc. Soc. Exp. Biol. Med., 188: 142-8 (1988)
1987
Monoclonal antibodies (MAb) have been used to study the distribution of ventricular heavy-chain (HC) myosins in cardiomyopathic UM-X7.1 Syrian hamsters. The Ab were identified as alpha and beta anti-HC myosins because of their ability to cross-react with ventricular V1 and V3 myosins, respectively. Cryostat frozen sections from the midventricle region of normal and myopathic hearts were processed for demonstration of these isomyosins by indirect immunofluorescence. In myopathic hearts, there was a shift of predominant alpha myosin toward the beta isoform with the time course of the hamster cardiomyopathy. A D-600 treatment while preventing cardiac necrotic lesions had little or no effect on the beta isomyosin conversion. It is inferred that the isomyosin shift during the progression of the hamster cardiomyopathy is unrelated to the necrotizing process and merely reflects the hypokynetism of the cardiomyocytes.
Local diversity of myosin expression in mammalian atrial muscles. Variations depending on age and thyroid state in the rat and the rabbit. Dechesne, C A, et al. Circ. Res., 57: 767-75 (1985)
1985
Rat, rabbit, pig, and bovine atrial myocardia were investigated with anti-alpha and anti-beta myosin heavy chain monoclonal antibodies. Analysis of atrial fibers by indirect immunofluorescence and assay of myosin heavy chains in tissue micro samples by immunoaffinity chromatography revealed both heterogeneity and plasticity in the atrial myosin heavy chains, undetected by electrophoresis of native atrial myosins under nondenaturing conditions. We found both alpha- and beta-like myosin heavy chains to be expressed in rat and rabbit, as they are in pig and bovine, atrial myocardia. They were regionally distributed within atrial muscles. The beta-like myosin heavy chains were present at much lower levels in rat and rabbit atria than in pig and bovine atria. Young rat atrial myosin was composed of only alpha-like heavy chains. In the rat and the rabbit, hyperthyroidism induced a beta- to alpha-like myosin heavy chain transition, which was considerable in the right atria and complete in the left atria. In the rat, thyroidectomy induced a moderate alpha- to beta-like myosin heavy chain transition, visible in the left atria. The significance of this atrial myosin heavy chain polymorphism is discussed in relation to the existence of anatomical localizations of the two myosin variants.
Fiber types and myosin types in human atrial and ventricular myocardium. An anatomical description. Bouvagnet, P, et al. Circ. Res., 55: 794-804 (1984)
1983
Millipore offers Anti-Myosin Antibodies that demonstrate specificity against Myosin heavy or light chains. See below for various Myosin antibodies, based on the expertise of Upstate & Chemicon. Weitere Informationen >>